Sign up
Pharma Capital

Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in 'globalising product'

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC.

The deal complements a number of agreements that Zelda has in place with international partners, and more such deals are set to be announced this year.

Hopkins  explains, "We've got access to in excess of 110,000 registered medicinal cannabis patients at the moment, which is in excess of 30 times larger than the whole Australian market; so this is our approach to globalising our product... Putting in that framework that allows us to rapidly commercialise the outcomes from our clinical trials."

 

View full ZLD profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.